Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease

Abstract

Embodiments concern methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium. Aspects include methods and compositions for providing a passive immune response against the bacteria. In certain embodiments, the methods and compositions involve an antibody that binds Coagulase (Coa).

1 .- 128 . (canceled) 
     
     
         129 . A method of treating or preventing a  Staphylococcus  infection in a subject comprising administering to the subject an effective amount of a composition comprising a Coa binding antibody comprising the amino acid sequences of the CDR 1, 2, and 3 domains from both the heavy and light chains of the antibody from host cell ATCC Accession number PTA-124061. 
     
     
         130 . The method of  claim 129 , wherein the Coa binding antibody is a single chain antibody. 
     
     
         131 . The method of  claim 129 , wherein the Coa binding antibody is a recombinant fusion protein. 
     
     
         132 . The method of  claim 129 , wherein the Coa binding antibody is humanized. 
     
     
         133 . The method of  claim 129 , wherein the Coa binding antibody is chimeric. 
     
     
         134 . The method of  claim 129 , further comprising administering an antibiotic or a Staphylococcal vaccine composition. 
     
     
         135 . The method of  claim 129 , wherein the composition is administered intramuscularly or subcutaneously. 
     
     
         136 . The method of  claim 129 , wherein the composition is administered at least twice. 
     
     
         137 . The method of  claim 129 , wherein the subject has or is at risk for bacteremia or a hospital-acquired infection. 
     
     
         138 . The method of  claim 129 , wherein the  Staphylococcus  infection is methicillin-resistant. 
     
     
         139 . A method of treating or preventing a  Staphylococcus  infection in a subject, the method comprising administering to the subject an effective amount of a composition comprising a Coa binding antibody comprising the amino acid sequences of the CDR 1, 2, and 3 domains from both the heavy and light chains of the antibody from host cell ATCC Accession number PTA-124060. 
     
     
         140 . The method of  claim 139 , wherein the Coa binding antibody is a single chain antibody. 
     
     
         141 . The method of  claim 139 , wherein the Coa binding antibody is a recombinant fusion protein. 
     
     
         142 . The method of  claim 139 , wherein the Coa binding antibody is humanized. 
     
     
         143 . The method of  claim 139 , wherein the Coa binding antibody is chimeric. 
     
     
         144 . The method of  claim 139 , wherein the composition is administered intramuscularly or subcutaneously. 
     
     
         145 . The method of  claim 139 , wherein the composition is administered at least twice. 
     
     
         146 . The method of  claim 139 , wherein the subject has or is at risk for bacteremia or a hospital-acquired infection. 
     
     
         147 . The method of  claim 139 , wherein the  Staphylococcus  infection is methicillin-resistant. 
     
     
         148 . The method of  claim 139 , further comprising administering an antibiotic or a Staphylococcal vaccine composition.